Cited by 302Cellular transport and secretionCaveolin-1 and cellular processesBiotin and Related Studies

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index; 8 of the 35 sources its claims cite were checked for support.

Disabled‐2 exhibits the properties of a cargo‐selective endocytic clathrin adaptor

Open access
Mishra, Sanjay K., Keyel, Peter A., Hawryluk, Matthew J., Agostinelli, Nicole R., Watkins, Simon C., Traub, Linton M.·2002·The EMBO Journal

Abstract

Clathrin-coated pits at the cell surface select material for transportation into the cell interior. A major mode of cargo selection at the bud site is via the micro 2 subunit of the AP-2 adaptor complex, which recognizes tyrosine-based internalization signals. Other internalization motifs and signals, including phosphorylation and ubiquitylation, also tag certain proteins for incorporation into a coated vesicle, but the mechanism of selection is unclear. Disabled-2 (Dab2) recognizes the FXNPXY internalization motif in LDL-receptor family members via an N-terminal phosphotyrosine-binding (PTB) domain. Here, we show that in addition to binding AP-2, Dab2 also binds directly to phosphoinositides and to clathrin, assembling triskelia into regular polyhedral coats. The FXNPXY motif and phosphoinositides contact different regions of the PTB domain, but can stably anchor Dab2 to the membrane surface, while the distal AP-2 and clathrin-binding determinants regulate clathrin lattice assembly. We propose that Dab2 is a typical member of a growing family of cargo-specific adaptor proteins, including beta-arrestin, AP180, epsin, HIP1 and numb, which regulate clathrin-coat assembly at the plasma membrane by synchronizing cargo selection and lattice polymerization events.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

Dab2 binds AP-2, clathrin, and phosphoinositides, and can assemble clathrin triskelia into polyhedral coats on liposome templates. The authors propose Dab2 is a cargo-selective endocytic adaptor for FXNPXY-bearing cargo such as LDL-receptor family members.

Key findings

  • Dab2’s central region binds AP-2 and clathrin: residues 206–368 are minimal for optimal AP-2 binding, while residues 206–258 bind clathrin; mutation of the type I clathrin-box 236LVDLN to AAALN nearly abolishes clathrin binding in the smallest fragment, and combined LVD→AAA/W→A mutation in 206–368 reduces clathrin binding 4- to 5-fold without affecting AP-2 binding.
  • Dab2 binds preassembled clathrin cages and assembles soluble clathrin trimers into sedimentable polyhedral cages; GST–Dab2(1–368) recruits clathrin, and EM shows regular polyhedral clathrin cages, whereas the minimal clathrin-binding fragment GST–Dab2(206–258) does not increase clathrin recovery above background.
  • The N-terminal PTB domain (residues 1–205) binds phosphoinositides; monomeric PTB binds ~25-fold better to PtdIns(4,5)P2 liposomes, rising from ~2% without phosphoinositide to >50% bound, and can bind phosphoinositides and an LDL-receptor FXNPXY peptide simultaneously.
  • In COS-7 cells, overexpression of myc-Dab2 PTBx2 selectively blocks diI-LDL uptake during a 15 min pulse while transferrin uptake remains normal; in liposome assays, AP-2 plus GST–Dab2 leads to ~50% of total clathrin assembling onto sedimenting liposomes, with ~one-quarter of liposome-bound coat components resistant to 1% Triton X-100.

Methods

  • In vitro binding assays used GST–Dab2 truncations and mutants immobilized on GSH–Sepharose incubated with rat brain cytosol, followed by SDS–PAGE and immunoblotting for AP-2 subunits and clathrin heavy/light chains.
  • Clathrin assembly was tested by mixing purified clathrin with GST–Dab2 fusions, differential centrifugation, negative-stain EM, and liposome/monolayer assays with mixed lipids, phosphoinositides, purified AP-2, and clathrin; Triton X-100 extraction assessed coat assembly.
  • Cell assays included immunofluorescence co-localization of Dab2 and epsin 1 in HeLa cells, and COS-7 transfection with myc-tagged Dab2 PTBx2 followed by diI-LDL and transferrin uptake; siRNA knockdown of Dab2 by >90% in HeLa cells did not inhibit diI-LDL uptake (not shown).

Limitations

  • The paper states no explicit limitations section. It notes that siRNA knockdown of Dab2 by >90% in HeLa cells did not inhibit diI-LDL uptake, that no mutations in Dab2 have been linked to hypercholesterolemia, and that Dab2 is not expressed ubiquitously, with many ovarian and breast carcinomas failing to express it, suggesting possible compensation by other PTB-domain proteins.
  • Evident from the text: many central assembly conclusions rely on in vitro assays with purified proteins and synthetic liposomes; PTBx2 overexpression may not reflect endogenous Dab2 function; some supporting data are “not shown”; and the anti-Dab2 antibody detects all three splice isoforms (p67, p93, p96), so distinct isoform locations cannot be concluded.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/emboj/cdf487

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

8 of 35 cited sources checked · 7 supported · 0 flagged · accuracy not yet measured

Show all 52 claims

  • Probably not a substantial claim. 14
  • It may state two separate claims as one. 12
26 of 26
  • The paper relies on this without support.

    The in vitro assembly of clathrin cages by Dab2 on liposome templates reflects the mechanism of clathrin-coated pit assembly at the plasma membrane.

    “With synthetic liposome templates, Dab2 drives clathrin-coat assembly in the presence of puri®ed AP-2 and clathrin and, consequently, displays all the properties of a cargo-speci®c adaptor protein.”
  • The paper relies on this without support.

    The LDL receptor cytosolic domain peptide used in binding assays represents the intact LDL receptor's FXNPXY internalization motif.

    “Addition of a 3-to 5-fold molar excess of a peptide corresponding to residues 2±22 of the LDL receptor cytosolic domain ( 814 NWRLKNINSIFDNPVYQKTT) does not diminish the extent of monomeric PTB domain association with the liposomes (Figure 6D, lane d compared with b).”
2 of 2

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Figure 6 caption names a different internalization motif

    Minor

    The Figure 6D caption says the PTB domain binds FXNPXF motifs, whereas the text identifies the motif as FXNPXY. The peptide tested in that figure also contains the FXNPXY sequence.

1 of 1

Citations

Cites

Flagged first, then by citations

Show all 68 references

Cited by

Sorted by citations

Items 301–302 of 302

Metadata

Authors
Mishra, S. K., Keyel, P. A., Hawryluk, M. J., Agostinelli, N. R., Watkins, S. C., & Traub, L. M.
Affiliations
University of Pittsburgh (US)
Corresponding author
Traub, Linton M.
Venue
The EMBO Journal
Published
2002-09-16
Volume
21
Issue
18
Pages
4915-4926
ISSN
  • 0261-4189 (ISSN-L)
  • 1460-2075
OpenAlex
W1983921682
Cited by
302
References
68
Citations by year
2026: 4 · 2025: 4 · 2024: 2 · 2023: 1 · 2022: 8 · 2021: 10 · 2020: 6 · 2019: 5 · 2018: 4 · 2017: 5 · 2016: 8 · 2015: 15 · 2014: 10 · 2013: 16 · 2012: 12
FWCI
7.14
Type
journal article
Language
en
Open access
Locations
  • The EMBO Journal (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK053249)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Caveolin-1 and cellular processes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Biotin and Related Studies
Keywords
Disabled-2, clathrin adaptor proteins, clathrin-coated pits, cargo selection, phosphoinositides, phosphotyrosine binding domain, AP-2, membrane internalization, clathrin-coated vesicles
MeSH terms
Amino Acid Sequence, Animals, Biological Transport, Carrier Proteins, Clathrin, Endocytosis, Fluorescent Dyes, HeLa Cells, Humans, Molecular Sequence Data, Neuropeptides, Peptides, Phosphatidylinositols, Protein Binding, Proteins, Receptors, LDL, Recombinant Fusion Proteins, Genes, Tumor Suppressor, Genes, Reporter, COS Cells, Amino Acid Motifs, Tumor Suppressor Proteins, Vesicular Transport Proteins, Adaptor Proteins, Vesicular Transport, Adaptor Protein Complex 2, Adaptor Proteins, Signal Transducing, Apoptosis Regulatory Proteins, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review